FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004500553> ?p ?o ?g. }

• W3004500553 endingPage "3161" @default.
• W3004500553 startingPage "3154" @default.
• W3004500553 abstract "Abstract Purpose: Cytarabine, 100–200 mg/mE+2/day, is commonly used in induction therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would be more effective is unknown. Also, there is controversy whether high-dose cytarabine is better than an intermediate-dose combined with other drugs for post-remission therapy. In this open-label, randomized controlled, parallel group study, roles of intermediate-dose cytarabine were investigated. Patients and Methods: Subjects with AML age 15–55 years were randomized to receive daunorubicin, omacetaxine mepesuccinate, and conventional- or intermediate-dose cytarabine. Subjects achieving complete remission were randomized to receive 3 courses of high-dose cytarabine or 2 courses of intermediate-dose cytarabine with daunorubicin in the 1st and mitoxantrone in the 2nd course. The primary endpoint was disease-free survival (DFS). Results: 591 subjects were randomized to intermediate- (N = 295) or conventional-dose (N = 296) cytarabine group. Three-year DFSs were 67% [95% confidence interval (CI), 61–73] in the intermediate-dose cohort compared with 54% (95% CI, 48–61) in the conventional-dose cohort [Hazard Ratio (HR), 0.67; 95%CI, 0.51–0.89; P = 0.005). Three-year survivals were 68% (95%CI, 63–74) and 59% (95%CI, 53–65; HR, 0.720; 95%CI, 0.56–0.94; P = 0.014). Two courses of intermediate-dose cytarabine with daunorubicin or mitoxantrone resulted in similar DFS and survival as three courses of high-dose cytarabine when used for post-remission therapy. Conclusions: Induction therapy with intermediate-dose cytarabine with daunorubicin and omacetaxine mepesuccinate increases DFS and survival in persons with AML ages 15–55 years compared with conventional-dose cytarabine. See related commentary by Watts and Bradley, p. 3073" @default.
• W3004500553 created "2020-02-14" @default.
• W3004500553 creator A5003642180 @default.
• W3004500553 creator A5005196775 @default.
• W3004500553 creator A5016508145 @default.
• W3004500553 creator A5018863416 @default.
• W3004500553 creator A5025095801 @default.
• W3004500553 creator A5027567446 @default.
• W3004500553 creator A5028802931 @default.
• W3004500553 creator A5029167025 @default.
• W3004500553 creator A5048883481 @default.
• W3004500553 creator A5051337665 @default.
• W3004500553 creator A5053683203 @default.
• W3004500553 creator A5062310871 @default.
• W3004500553 creator A5067006313 @default.
• W3004500553 creator A5074033893 @default.
• W3004500553 creator A5075101614 @default.
• W3004500553 creator A5075285660 @default.
• W3004500553 creator A5081348340 @default.
• W3004500553 creator A5081550009 @default.
• W3004500553 creator A5085323487 @default.
• W3004500553 creator A5086214965 @default.
• W3004500553 creator A5088486180 @default.
• W3004500553 date "2020-07-01" @default.
• W3004500553 modified "2023-10-17" @default.
• W3004500553 title "Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia" @default.
• W3004500553 cites W1492445977 @default.
• W3004500553 cites W1519562949 @default.
• W3004500553 cites W1969545468 @default.
• W3004500553 cites W1990261520 @default.
• W3004500553 cites W1993862617 @default.
• W3004500553 cites W2010026460 @default.
• W3004500553 cites W2022686977 @default.
• W3004500553 cites W2025086811 @default.
• W3004500553 cites W2028241603 @default.
• W3004500553 cites W2033340973 @default.
• W3004500553 cites W2040039773 @default.
• W3004500553 cites W2069448515 @default.
• W3004500553 cites W2072940754 @default.
• W3004500553 cites W2079025304 @default.
• W3004500553 cites W2081588935 @default.
• W3004500553 cites W2105573850 @default.
• W3004500553 cites W2107398329 @default.
• W3004500553 cites W2139717439 @default.
• W3004500553 cites W2143835472 @default.
• W3004500553 cites W2144274033 @default.
• W3004500553 cites W2144395887 @default.
• W3004500553 cites W2148883973 @default.
• W3004500553 cites W2159363584 @default.
• W3004500553 cites W2159507916 @default.
• W3004500553 cites W2160746673 @default.
• W3004500553 cites W2167638087 @default.
• W3004500553 cites W2266365610 @default.
• W3004500553 cites W2318674152 @default.
• W3004500553 cites W2726845895 @default.
• W3004500553 cites W2735569737 @default.
• W3004500553 cites W2800919438 @default.
• W3004500553 cites W4231346141 @default.
• W3004500553 cites W4376595466 @default.
• W3004500553 doi "https://doi.org/10.1158/1078-0432.ccr-19-3433" @default.
• W3004500553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32029439" @default.
• W3004500553 hasPublicationYear "2020" @default.
• W3004500553 type Work @default.
• W3004500553 sameAs 3004500553 @default.
• W3004500553 citedByCount "22" @default.
• W3004500553 countsByYear W30045005532020 @default.
• W3004500553 countsByYear W30045005532021 @default.
• W3004500553 countsByYear W30045005532022 @default.
• W3004500553 countsByYear W30045005532023 @default.
• W3004500553 crossrefType "journal-article" @default.
• W3004500553 hasAuthorship W3004500553A5003642180 @default.
• W3004500553 hasAuthorship W3004500553A5005196775 @default.
• W3004500553 hasAuthorship W3004500553A5016508145 @default.
• W3004500553 hasAuthorship W3004500553A5018863416 @default.
• W3004500553 hasAuthorship W3004500553A5025095801 @default.
• W3004500553 hasAuthorship W3004500553A5027567446 @default.
• W3004500553 hasAuthorship W3004500553A5028802931 @default.
• W3004500553 hasAuthorship W3004500553A5029167025 @default.
• W3004500553 hasAuthorship W3004500553A5048883481 @default.
• W3004500553 hasAuthorship W3004500553A5051337665 @default.
• W3004500553 hasAuthorship W3004500553A5053683203 @default.
• W3004500553 hasAuthorship W3004500553A5062310871 @default.
• W3004500553 hasAuthorship W3004500553A5067006313 @default.
• W3004500553 hasAuthorship W3004500553A5074033893 @default.
• W3004500553 hasAuthorship W3004500553A5075101614 @default.
• W3004500553 hasAuthorship W3004500553A5075285660 @default.
• W3004500553 hasAuthorship W3004500553A5081348340 @default.
• W3004500553 hasAuthorship W3004500553A5081550009 @default.
• W3004500553 hasAuthorship W3004500553A5085323487 @default.
• W3004500553 hasAuthorship W3004500553A5086214965 @default.
• W3004500553 hasAuthorship W3004500553A5088486180 @default.
• W3004500553 hasBestOaLocation W30045005532 @default.
• W3004500553 hasConcept C126322002 @default.
• W3004500553 hasConcept C141071460 @default.
• W3004500553 hasConcept C168563851 @default.
• W3004500553 hasConcept C207103383 @default.
• W3004500553 hasConcept C2776694085 @default.
• W3004500553 hasConcept C2778041864 @default.

• next